RU2018132037A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2018132037A3 RU2018132037A3 RU2018132037A RU2018132037A RU2018132037A3 RU 2018132037 A3 RU2018132037 A3 RU 2018132037A3 RU 2018132037 A RU2018132037 A RU 2018132037A RU 2018132037 A RU2018132037 A RU 2018132037A RU 2018132037 A3 RU2018132037 A3 RU 2018132037A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/38—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing five carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/60—Ring systems containing bridged rings containing three rings containing at least one ring with less than six members
- C07C2603/62—Ring systems containing bridged rings containing three rings containing at least one ring with less than six members containing three- or four-membered rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662317254P | 2016-04-01 | 2016-04-01 | |
| US62/317,254 | 2016-04-01 | ||
| PCT/US2017/024809 WO2017172957A1 (en) | 2016-04-01 | 2017-03-29 | Estrogen receptor modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018132037A RU2018132037A (ru) | 2020-05-12 |
| RU2018132037A3 true RU2018132037A3 (ru) | 2020-05-15 |
| RU2738646C2 RU2738646C2 (ru) | 2020-12-15 |
Family
ID=59966438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018132037A RU2738646C2 (ru) | 2016-04-01 | 2017-03-29 | Модуляторы эстрогеновых рецепторов |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US20190142811A1 (ru) |
| EP (1) | EP3442971B1 (ru) |
| JP (2) | JP6926189B2 (ru) |
| KR (2) | KR20220071293A (ru) |
| CN (4) | CN109311870B (ru) |
| AR (1) | AR108011A1 (ru) |
| AU (3) | AU2017242027B2 (ru) |
| CA (1) | CA3017388C (ru) |
| ES (1) | ES2991862T3 (ru) |
| IL (3) | IL285318B (ru) |
| MX (2) | MX392461B (ru) |
| RU (1) | RU2738646C2 (ru) |
| SG (1) | SG11201807708SA (ru) |
| TW (2) | TW202235418A (ru) |
| WO (1) | WO2017172957A1 (ru) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX387596B (es) | 2016-02-05 | 2025-03-18 | Inventisbio Llc | Degradadores selectivos del receptor de estrógeno y sus usos. |
| AU2017242027B2 (en) * | 2016-04-01 | 2020-10-08 | Recurium Ip Holdings, Llc | Estrogen receptor modulators |
| CN107814798B (zh) * | 2016-09-14 | 2020-11-03 | 四川科伦博泰生物医药股份有限公司 | 3-取代丙烯酸类化合物及其制备方法和用途 |
| WO2018130124A1 (zh) * | 2017-01-11 | 2018-07-19 | 南京圣和药业股份有限公司 | 作为选择性雌激素受体下调剂的三环类化合物及其应用 |
| AU2018329815B2 (en) | 2017-09-11 | 2023-02-16 | Recurium Ip Holdings, Llc | Continuous flow processes for making bicyclic compounds |
| CN111315378A (zh) * | 2017-11-16 | 2020-06-19 | 诺华股份有限公司 | 包含lsz102和瑞博西尼的药物组合 |
| WO2020238733A1 (zh) * | 2019-05-24 | 2020-12-03 | 浙江海正药业股份有限公司 | 丙烯酸类衍生物的晶型及其制备方法和用途 |
| BR112022002138A2 (pt) * | 2019-08-06 | 2022-04-19 | Recurium Ip Holdings Llc | Moduladores do receptor de estrogênio para tratamento de mutantes |
| KR20220103977A (ko) * | 2019-11-04 | 2022-07-25 | 리커리엄 아이피 홀딩스, 엘엘씨 | 에스트로겐 수용체 조절제의 염 및 형태 |
| BR112022012287A2 (pt) * | 2019-12-20 | 2022-08-30 | Recurium Ip Holdings Llc | Combinações |
| BR112022012266A2 (pt) * | 2019-12-20 | 2022-08-30 | Recurium Ip Holdings Llc | Combinações |
| WO2021127047A1 (en) * | 2019-12-20 | 2021-06-24 | Recurium Ip Holdings, Llc | Combinations |
| IL294084A (en) * | 2019-12-20 | 2022-08-01 | Recurium Ip Holdings Llc | conjunctions |
| WO2021127042A1 (en) * | 2019-12-20 | 2021-06-24 | Recurium Ip Holdings, Llc | Combinations |
| EP4121413A4 (en) * | 2020-04-22 | 2024-04-17 | Recurium IP Holdings, LLC | PREPARATION OF A SELECTIVE ESTROGEN RECEPTOR DEGRADING AGENT |
| WO2021253380A1 (en) * | 2020-06-19 | 2021-12-23 | InventisBio Co., Ltd. | Oral formulations and uses thereof |
| EP4214192A4 (en) * | 2020-09-20 | 2024-09-25 | Tactogen Inc. | BENEFICIAL TRYPTAMINE COMPOSITIONS FOR IMPROVING MENTAL DISORDERS |
| WO2022133446A1 (en) * | 2020-12-16 | 2022-06-23 | Recurium Ip Holdings, Llc | Combinations |
| EP4267578A4 (en) | 2020-12-23 | 2024-11-20 | Recurium IP Holdings, LLC | ESTROGEN RECEPTOR MODULATORS |
| AU2022305957A1 (en) * | 2021-07-08 | 2024-01-25 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-associated diseases |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL112958A0 (en) | 1994-03-11 | 1995-06-29 | Lilly Co Eli | Method for treating 5ht2b receptor related conditions |
| GB9604996D0 (en) | 1996-03-08 | 1996-05-08 | Black James Foundation | Benzodiazonine derivatives |
| EP1113007A1 (en) * | 1999-12-24 | 2001-07-04 | Pfizer Inc. | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists |
| ATE348828T1 (de) | 2001-10-19 | 2007-01-15 | Transtech Pharma Inc | Beta-carbolin-derivate als ptp-inhibitoren |
| US8076352B2 (en) * | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
| EP1786425A1 (en) | 2004-08-02 | 2007-05-23 | SmithKline Beecham Corporation | Useful compounds for hpv infection |
| WO2007002051A1 (en) | 2005-06-22 | 2007-01-04 | Smithkline Beecham Corporation | Carboline derivatives and their use as inhibitors of flaviviridae infections |
| WO2008002490A2 (en) | 2006-06-23 | 2008-01-03 | Radius Health, Inc. | Treatment of vasomotor symptoms with selective estrogen receptor modulators |
| US20100158858A1 (en) | 2007-04-13 | 2010-06-24 | Liangxian Cao | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
| DE102007028515A1 (de) | 2007-06-21 | 2008-12-24 | Merck Patent Gmbh | 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate |
| TW201028414A (en) * | 2009-01-16 | 2010-08-01 | Merck Sharp & Dohme | Oxadiazole beta carboline derivatives as antidiabetic compounds |
| US20120135089A1 (en) | 2009-03-17 | 2012-05-31 | Stockwell Brent R | E3 ligase inhibitors |
| WO2010138706A1 (en) * | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating breast cancer |
| MX394033B (es) * | 2009-05-27 | 2025-03-24 | Ptc Therapeutics Inc | Un Método para Inhibir o Reducir una Infección Viral por Coronavirus |
| TWI466877B (zh) * | 2009-07-28 | 2015-01-01 | Ono Pharmaceutical Co | 雙環式化合物及其醫藥用途 |
| US8754099B2 (en) | 2010-01-15 | 2014-06-17 | Merck Sharp & Dohme Corp | Oxadiazole beta carboline derivatives as antidiabetic compounds |
| AU2011215898B2 (en) * | 2010-02-11 | 2016-08-11 | Bristol-Myers Squibb Company | Macrocycles as Factor XIa inhibitors |
| WO2011103487A1 (en) | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| AU2011264858B2 (en) | 2010-06-10 | 2016-04-21 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| EP2669279B1 (en) * | 2011-01-27 | 2017-01-11 | ONO Pharmaceutical Co., Ltd. | Bicyclic compound and use thereof for medical purposes |
| CN102432608B (zh) | 2011-11-01 | 2013-04-17 | 浙江大学 | 手性螺环磷酸催化合成光学活性四氢-β-咔啉衍生物的方法 |
| BR112014014124A2 (pt) | 2011-12-14 | 2017-08-22 | Seragon Pharmaceutical Inc | Moduladores do receptor de estrogênio fluorados e usos dos mesmos |
| JP6034877B2 (ja) * | 2011-12-31 | 2016-11-30 | ベイジーン リミテッド | Parp阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン |
| SG11201404738QA (en) * | 2012-02-07 | 2014-10-30 | Eolas Therapeutics Inc | Substituted prolines / piperidines as orexin receptor antagonists |
| JP6154887B2 (ja) | 2012-03-20 | 2017-06-28 | セラゴン ファーマシューティカルズ,インク. | エストロゲン受容体モジュレーターおよびその使用 |
| LT2872482T (lt) | 2012-07-13 | 2020-12-28 | Oncternal Therapeutics, Inc. | Krūties vėžių gydymo būdas selektyviu androgeno receptoriaus moduliatoriumi |
| HUE039052T2 (hu) | 2013-02-19 | 2018-12-28 | Novartis Ag | Benzotiofénszármazékok és azok készítményei szelektív ösztrogén receptor lebontóként |
| US9586952B2 (en) | 2013-03-14 | 2017-03-07 | Genentech, Inc. | Polycyclic estrogen receptor modulators and uses thereof |
| HUE035738T2 (en) * | 2013-05-28 | 2018-05-28 | Astrazeneca Ab | Chemical compounds |
| CN105916501A (zh) | 2013-12-06 | 2016-08-31 | 豪夫迈·罗氏有限公司 | 用于治疗局部晚期或转移性雌激素受体阳性乳腺癌的雌激素受体调节剂 |
| CN104693211A (zh) | 2013-12-10 | 2015-06-10 | 南京明德新药研发股份有限公司 | 作为抗病毒剂的咪唑衍生物及其制药用途 |
| TW201613891A (en) * | 2014-02-12 | 2016-04-16 | Eolas Therapeutics Inc | Substituted prolines / piperidines as orexin receptor antagonists |
| US9695166B2 (en) * | 2014-05-05 | 2017-07-04 | Global Blood Therapeutics, Inc. | Pyrazolopyridine pyrazolopyrimidine and related compounds |
| SG11201609286VA (en) | 2014-05-16 | 2016-12-29 | Actelion Pharmaceuticals Ltd | Antibacterial quinazoline-4(3h)-one derivatives |
| MA40249A (fr) | 2014-06-27 | 2017-05-03 | Nogra Pharma Ltd | Modulateurs des récepteurs d'aryle, et leurs procédés de fabrication et méthodes d'utilisation |
| USRE49128E1 (en) | 2014-10-09 | 2022-07-12 | Guangdong Raynovent Biotech Co., Ltd. | Hydroxyl purine compounds and applications thereof |
| US10314797B2 (en) | 2016-06-10 | 2019-06-11 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| US10654809B2 (en) | 2016-06-10 | 2020-05-19 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| RU2019115778A (ru) | 2015-04-21 | 2019-06-24 | Джи Ти Икс, ИНК. | Селективные лиганды - разрушители андрогенных рецепторов (sard) и способы их применения |
| MX372914B (es) * | 2015-06-16 | 2020-04-27 | Jiangsu Hengrui Medicine Co | Derivado de piperidina y metodo de preparacion y uso farmaceutico del mismo. |
| WO2017080338A1 (zh) | 2015-11-12 | 2017-05-18 | 浙江海正药业股份有限公司 | 丙烯酸类衍生物、其制备方法及其在医药上的用途 |
| MX387596B (es) * | 2016-02-05 | 2025-03-18 | Inventisbio Llc | Degradadores selectivos del receptor de estrógeno y sus usos. |
| AU2017242027B2 (en) | 2016-04-01 | 2020-10-08 | Recurium Ip Holdings, Llc | Estrogen receptor modulators |
| CN109415361B (zh) * | 2016-06-29 | 2022-03-08 | 浙江海正药业股份有限公司 | 丙烯酸类衍生物及其制备方法和其在医药上的用途 |
| JP7050770B2 (ja) * | 2016-10-05 | 2022-04-08 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 抗体薬物コンジュゲートの調製方法 |
| WO2018130124A1 (zh) * | 2017-01-11 | 2018-07-19 | 南京圣和药业股份有限公司 | 作为选择性雌激素受体下调剂的三环类化合物及其应用 |
-
2017
- 2017-03-29 AU AU2017242027A patent/AU2017242027B2/en active Active
- 2017-03-29 IL IL285318A patent/IL285318B/en unknown
- 2017-03-29 CN CN201780033815.1A patent/CN109311870B/zh active Active
- 2017-03-29 JP JP2019503398A patent/JP6926189B2/ja active Active
- 2017-03-29 CN CN202011582784.5A patent/CN112745316A/zh active Pending
- 2017-03-29 CN CN202011582762.9A patent/CN112679495B/zh active Active
- 2017-03-29 CN CN202111035485.4A patent/CN113717170A/zh active Pending
- 2017-03-29 IL IL295050A patent/IL295050A/en unknown
- 2017-03-29 KR KR1020227016946A patent/KR20220071293A/ko not_active Ceased
- 2017-03-29 EP EP17776574.0A patent/EP3442971B1/en active Active
- 2017-03-29 CA CA3017388A patent/CA3017388C/en active Active
- 2017-03-29 MX MX2018011419A patent/MX392461B/es unknown
- 2017-03-29 SG SG11201807708SA patent/SG11201807708SA/en unknown
- 2017-03-29 US US16/086,434 patent/US20190142811A1/en not_active Abandoned
- 2017-03-29 WO PCT/US2017/024809 patent/WO2017172957A1/en not_active Ceased
- 2017-03-29 ES ES17776574T patent/ES2991862T3/es active Active
- 2017-03-29 KR KR1020187030841A patent/KR102401841B1/ko active Active
- 2017-03-29 RU RU2018132037A patent/RU2738646C2/ru active
- 2017-03-30 AR ARP170100788A patent/AR108011A1/es unknown
- 2017-03-30 TW TW110145253A patent/TW202235418A/zh unknown
- 2017-03-30 TW TW106110662A patent/TWI746535B/zh active
-
2018
- 2018-09-06 IL IL261654A patent/IL261654B/en unknown
- 2018-09-24 MX MX2022005780A patent/MX2022005780A/es unknown
-
2020
- 2020-05-05 US US16/866,900 patent/US11065233B2/en active Active
- 2020-05-05 US US16/866,995 patent/US10959989B2/en active Active
- 2020-05-05 US US16/867,017 patent/US11065234B2/en active Active
- 2020-12-22 AU AU2020294196A patent/AU2020294196B2/en active Active
-
2021
- 2021-07-06 US US17/305,369 patent/US20210330651A1/en not_active Abandoned
- 2021-08-04 JP JP2021127863A patent/JP2021176911A/ja active Pending
-
2022
- 2022-06-09 AU AU2022204025A patent/AU2022204025A1/en not_active Abandoned